Home LiteratureArticle Details
PMID: 3297617 Published · ppublish English Journal Article Review

Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Drugs ·Vol. 33 ·No. 4 ·1987-04-00 ·Pages 346-91

Monk JP, Campoli-Richards DM

Abstract

Ofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid. It is an orally administered broad spectrum antibacterial drug active against most Gram-negative bacteria, many Gram-positive bacteria and some anaerobes. Ciprofloxacin is the only other quinolone with superior in vitro antibacterial activity. However, the pharmacokinetic profile of ofloxacin is superior to that of ciprofloxacin, with more rapid absorption and a peak serum concentration several times higher. Moreover, ofloxacin achieves high concentrations in most tissues and body fluids. The results of clinical trials with ofloxacin have confirmed the potential for use in a wide range of infections, which was indicated by its in vitro antibacterial and pharmacokinetic profiles. It has proven effective against a high percentage of infections caused by Gram-negative organisms, slightly less effective against Gram-positive infections, and effective against some anaerobic infections. Clinical efficacy has also been confirmed in a variety of systemic infections as well as in acute and chronic urinary tract infections, and ofloxacin has generally appeared to be at least as effective as alternative orally administered antibacterial drugs. Ofloxacin is well tolerated and, although experience with the drug in clinical practice to date is limited, bacterial resistance does not appear to develop readily. Thus, ofloxacin is an orally active drug which offers a valuable alternative to other broad spectrum antibacterial drugs.

MeSH Terms
Anti-Bacterial Agents/metabolism,pharmacology,therapeutic use Bacterial Infections/drug therapy Humans Kinetics Ofloxacin Oxazines/metabolism,pharmacology,therapeutic use
Chemicals
Anti-Bacterial Agents Oxazines Ofloxacin
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Monk J P
Campoli-Richards D M
References (91)
91 references, click to expand
  1. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    J Antimicrob Chemother. 1984 Mar;13(3):237-44 PMID: 6586712
  2. Enoxacin raises plasma theophylline concentrations.
    Lancet. 1984 Jul 14;2(8394):108-9 PMID: 6145999
  3. Antichlamydial activity of quinolone carboxylic acids.
    J Antimicrob Chemother. 1985 May;15(5):645-7 PMID: 3159713
  4. In vitro evaluation of A-56619 and A-56620, two new quinolones.
    Antimicrob Agents Chemother. 1986 Jan;29(1):40-3 PMID: 2942099
  5. Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state.
    J Antimicrob Chemother. 1986 Jun;17(6):795-800 PMID: 3460984
  6. Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study.
    Drugs. 1987;34 Suppl 1:80-2 PMID: 3325260
  7. Antituberculosis activity of ofloxacin (DL 8280) on experimental tuberculosis in mice.
    Am Rev Respir Dis. 1985 Oct;132(4):915 PMID: 3931525
  8. Chemotherapeutic efficacy of ofloxacin on renal and subcutaneous infection models with Staphylococcus aureus in mice.
    Chemotherapy. 1986;32(3):291-8 PMID: 3458566
  9. The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.
    Drugs Exp Clin Res. 1985;11(4):259-62 PMID: 2941258
  10. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts.
    Antimicrob Agents Chemother. 1986 Jun;29(6):1073-8 PMID: 3015015
  11. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
    Drugs Exp Clin Res. 1985;11(5):335-8 PMID: 2941261
  12. Antimicrobial chemotherapy of chlamydial infection: where next?
    Eur J Clin Microbiol. 1986 Oct;5(5):550-3 PMID: 3536500
  13. [Effect of pH value and magnesium on the antibacterial activity of quinolone preparations].
    Infection. 1986;14 Suppl 1:S31-5 PMID: 3514470
  14. [Effect ofloxacin on Haemophilus influenza, Streptococcus pneumoniae and Neisseria meningitidis. Comparison with similar molecules].
    Pathol Biol (Paris). 1985 May;33(5):385-8 PMID: 3162140
  15. In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.
    Antimicrob Agents Chemother. 1984 Oct;26(4):608-9 PMID: 6240224
  16. Influence of ofloxacin, norfloxacin, nalidixic acid, pyromidic acid and pipemidic acid on human gamma-interferon production and blastogenesis.
    J Antimicrob Chemother. 1986 Jun;17(6):811-4 PMID: 3090010
  17. [Tissue concentration and effectiveness of ofloxacin in surgical patients].
    Infection. 1986;14 Suppl 1:S70-2 PMID: 3456986
  18. Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids.
    Antimicrob Agents Chemother. 1986 Apr;29(4):598-601 PMID: 3010848
  19. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Scand J Infect Dis. 1986;18(2):149-51 PMID: 2939556
  20. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Arzneimittelforschung. 1985;35(3):570-2 PMID: 2986655
  21. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    Drugs Exp Clin Res. 1985;11(4):253-7 PMID: 2941257
  22. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.
    Am Rev Respir Dis. 1985 Mar;131(3):352-6 PMID: 3856412
  23. Dominant lethal study in male mice treated with ofloxacin, a new antimicrobial drug.
    Mutat Res. 1985 Sep;144(1):51-5 PMID: 3861937
  24. The possible role of quinolones in yersiniosis.
    Drugs. 1987;34 Suppl 1:134-8 PMID: 3436262
  25. Antibacterial activity of coumermycin alone and in combination with other antibiotics.
    Antimicrob Agents Chemother. 1984 Jun;25(6):687-9 PMID: 6331295
  26. In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam.
    Antimicrob Agents Chemother. 1985 Jul;28(1):37-40 PMID: 2994557
  27. In-vitro activity of newer quinolones against aerobic bacteria.
    J Antimicrob Chemother. 1986 Apr;17 Suppl B:29-39 PMID: 2940214
  28. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 1986 Feb;29(2):325-6 PMID: 2940966
  29. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli.
    Antimicrob Agents Chemother. 1986 Mar;29(3):535-8 PMID: 3521490
  30. Quinolones affect thymidine incorporation into the DNA of human lymphocytes.
    Antimicrob Agents Chemother. 1986 Mar;29(3):506-8 PMID: 3717944
  31. Quinolones and raised plasma concentrations of theophylline.
    Lancet. 1984 Sep 1;2(8401):530 PMID: 6147598
  32. [Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe].
    Infection. 1986;14 Suppl 1:S102-7 PMID: 3514468
  33. Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.
    Eur J Clin Microbiol. 1983 Dec;2(6):548-53 PMID: 6230226
  34. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.
    Antimicrob Agents Chemother. 1985 Oct;28(4):581-6 PMID: 3000292
  35. The comparative in-vitro activity of twelve 4-quinolone antimicrobials against Haemophilus ducreyi.
    J Antimicrob Chemother. 1985 Aug;16(2):165-8 PMID: 3877717
  36. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
    Clin Ther. 1986;8(6):632-45 PMID: 3466701
  37. Elimination of plasmids by new 4-quinolones.
    Antimicrob Agents Chemother. 1985 Nov;28(5):700-2 PMID: 3911881
  38. An investigation of the hydrophobicity of the quinolones.
    J Antimicrob Chemother. 1985 Dec;16(6):805-8 PMID: 3005220
  39. Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.
    Diagn Microbiol Infect Dis. 1985 Nov;3(6):469-78 PMID: 4064609
  40. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
    Antimicrob Agents Chemother. 1985 Nov;28(5):716-21 PMID: 2936302
  41. Pharmacokinetics of ofloxacin and theophylline alone and in combination.
    Infection. 1986;14 Suppl 1:S67-9 PMID: 3456985
  42. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
    Chemotherapy. 1985;31(1):19-28 PMID: 3156025
  43. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
    Antimicrob Agents Chemother. 1986 Feb;29(2):374-5 PMID: 2940968
  44. Quinolones and colonization resistance in human volunteers.
    Pharm Weekbl Sci. 1986 Feb 21;8(1):67-71 PMID: 2938072
  45. Antichlamydial activity of ofloxacin.
    Microbiol Immunol. 1986;30(5):445-50 PMID: 3462450
  46. [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].
    Infection. 1986;14 Suppl 1:S60-4 PMID: 2420725
  47. The influence of quinolone derivatives on theophylline clearance.
    Br J Clin Pharmacol. 1986 Dec;22(6):677-83 PMID: 3567014
  48. [A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally].
    Infection. 1986;14 Suppl 1:S82-6 PMID: 2937740
  49. Reproductive toxicity of ofloxacin.
    Arzneimittelforschung. 1986 Aug;36(8):1244-8 PMID: 3465327
  50. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
    Chemioterapia. 1985 Aug;4(4):278-83 PMID: 3863716
  51. The effect of food on the pharmacokinetics of ofloxacin.
    Curr Med Res Opin. 1986;10(3):166-71 PMID: 3460737
  52. Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli.
    Antimicrob Agents Chemother. 1986 Nov;30(5):777-80 PMID: 3026239
  53. Nalidixic acid: an antibacterial paradox.
    Antimicrob Agents Chemother. 1975 Sep;8(3):251-61 PMID: 1101818
  54. [Pharmacokinetics of ofloxacin in the elderly (65-85 years) with normal renal function after a single oral dose of 200 mg].
    Pathol Biol (Paris). 1986 Jun;34(5 Pt 2):596-9 PMID: 3534750
  55. Antimicrobial susceptibility of Serratia marcescens isolated from clinical materials.
    Jpn J Antibiot. 1984 Sep;37(9):1625-30 PMID: 6392599
  56. Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparison.
    J Antimicrob Chemother. 1985 Oct;16(4):475-84 PMID: 3864775
  57. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.
    Antimicrob Agents Chemother. 1984 Apr;25(4):518-21 PMID: 6732221
  58. [Treatment of typhoid fever using ofloxacin. Clinical experience and determination of antibiotic diffusion into the mesenteric lymph nodes].
    Pathol Biol (Paris). 1986 May;34(5):505-7 PMID: 3534732
  59. The effect of altered porin expression in Escherichia coli upon susceptibility to 4-quinolones.
    J Antimicrob Chemother. 1986 Oct;18(4):547-9 PMID: 3533892
  60. [Comparative clinical study of DL-8280 and cefaclor for suppurative skin and soft tissue infections by a double-blind method].
    Kansenshogaku Zasshi. 1984 Sep;58(9):793-819 PMID: 6440917
  61. Acute nongonococcal epididymitis. Aetiological and therapeutic aspects.
    Drugs. 1987;34 Suppl 1:111-7 PMID: 3481311
  62. Susceptibility of Clostridium difficile strains to new antibiotics: quinolones, efrotomycin, teicoplanin and imipenem.
    J Antimicrob Chemother. 1985 May;15(5):648-9 PMID: 3159714
  63. [Diffusion of an orally administered single dose of ofloxacin into human bronchial mucus].
    Pathol Biol (Paris). 1986 May;34(5):353-6 PMID: 3534705
  64. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent.
    Pharmatherapeutica. 1985;4(6):376-82 PMID: 3866256
  65. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280).
    Am Rev Respir Dis. 1985 Mar;131(3):348-51 PMID: 3919625
  66. [The antibacterial activity in vitro of ofloxacin in comparison with other orally administered antimicrobial substances on ampicillin-resistant clinical isolates].
    Arzneimittelforschung. 1984;34(11):1552-4 PMID: 6596953
  67. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens.
    Antimicrob Agents Chemother. 1985 Mar;27(3):388-92 PMID: 3158276
  68. [Comparative clinical study of ofloxacin and cefaclor in bacterial bronchitis].
    Kansenshogaku Zasshi. 1984 Sep;58(9):832-61 PMID: 6440920
  69. Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.
    Pharm Weekbl Sci. 1986 Feb 21;8(1):1-21 PMID: 3515312
  70. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs.
    Antimicrob Agents Chemother. 1985 Jul;28(1):15-20 PMID: 3862361
  71. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.
    Antimicrob Agents Chemother. 1986 Mar;29(3):386-8 PMID: 2940969
  72. Antimycoplasmal activity of ofloxacin (DL-8280).
    Antimicrob Agents Chemother. 1983 Mar;23(3):509-11 PMID: 6573869
  73. Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice.
    Infection. 1986;14 Suppl 1:S36-9 PMID: 2937738
  74. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli.
    Mol Gen Genet. 1986 Sep;204(3):367-73 PMID: 3020376
  75. The quinolones in chronic bronchitis.
    Pharm Weekbl Sci. 1986 Feb 21;8(1):53-9 PMID: 3960693
  76. [Comparative studies of DL-8280 and pipemidic acid in complicated urinary tract infections by double-blind method].
    Hinyokika Kiyo. 1984 Sep;30(9):1307-55 PMID: 6395684
  77. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.
    Antimicrob Agents Chemother. 1986 Apr;29(4):639-44 PMID: 3010850
  78. Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.
    Antimicrob Agents Chemother. 1986 Mar;29(3):395-9 PMID: 2940970
  79. Effects of ethylenediaminetetraacetic acid and gentamicin on the antibacterial activity of pyridone carboxylic acid derivatives against gram-negative bacilli.
    J Antimicrob Chemother. 1986 Mar;17(3):327-32 PMID: 3084441
  80. [Animal experiment studies on the modification of the immune system by ofloxacin].
    Infection. 1986;14 Suppl 1:S40-4 PMID: 3456983
  81. Comparative in vitro studies with 4-quinolone antimicrobials.
    Drugs Exp Clin Res. 1985;11(5):317-29 PMID: 2941259
  82. Synthesis and antibacterial activities of optically active ofloxacin.
    Antimicrob Agents Chemother. 1986 Jan;29(1):163-4 PMID: 3460520
  83. In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.
    J Antimicrob Chemother. 1985 Nov;16(5):563-74 PMID: 3865923
  84. Activities of new quinoline derivatives against genital pathogens.
    Antimicrob Agents Chemother. 1985 Jan;27(1):76-8 PMID: 3920959
  85. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:33-8 PMID: 6238931
  86. [Ofloxacin in the conservative therapy of acute and chronic otitis media--a preliminary clinical report of experiences].
    Infection. 1986;14 Suppl 1:S87-8 PMID: 3456987
  87. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
    Scand J Infect Dis. 1985;17(1):91-4 PMID: 3158070
  88. The comparative activity of twelve 4-quinolone antimicrobials against gram-positive and gram-negative anaerobes.
    Drugs Exp Clin Res. 1985;11(7):431-4 PMID: 3836865
  89. In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim.
    Chemotherapy. 1985;31(6):466-71 PMID: 2934234
  90. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    J Antimicrob Chemother. 1985 May;15(5):551-8 PMID: 3159712
  91. The pharmacokinetics and tissue penetration of ofloxacin.
    J Antimicrob Chemother. 1984 Dec;14(6):647-52 PMID: 6596301
Article Info
Journal
Drugs
Abbr.
Drugs
ISSN
0012-6667
DOI
10.2165/00003495-198733040-00003
Published
1987-04-00
Pages
346-91
Language
English
Region
New Zealand
NLM ID
7600076
Subset
IM
External Links
PubMed source DOI: 10.2165/00003495-198733040-00003 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2